Rosetta Genomics diagnostic tests are currently undergoing validation testing at Columbia University Medical Center at its clinical laboratory improvement amendments (CLIA) certified laboratory. The company expects three diagnostic
The drug, MAP0005, is a combination of a corticosteroid and a long-acting beta2-agonist delivered to the respiratory tract using MAP Pharmaceuticals’ Tempo inhaler. The primary endpoints of the
Under the terms of the agreement, NanoCarrier grants Debiopharm an exclusive license, with the right to sublicense, develop and commercialize DACH-Platin Polymeric Micelle worldwide excluding Japan. Debiopharm will
Under the terms, the royalties paid by Ipsen until July, 2010 will remain unchanged. After this date, Ipsen will continue to pay royalties on its sales of all
In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride for the treatment of attention deficit and hyperactivity disorder
The International Childhood Liver Tumour Strategy Group (SIOPEL) has planned for patient enrollment in the UK, with SIOPEL centers in up to 33 further countries also expected to
Under the agreement, Strides will develop and supply injectable products that Sagent will market in the US. Jeffrey Yordon, CEO, founder and chairman of the board of Sagent,
This submission of the prophylactic data will allow the FDA to complete a comprehensive review for both the acute and prophylactic indications of Cinryze without affecting the priority
All of the shares in the offering are being sold by the company. The offering is expected to close on November 2, 2007 and the company will receive
Pharmos said that it does not expect a material charge against operations to result from this undertaking. The Israeli subsidiary will continue efforts to expand and exploit the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.